Treatment of osteoarthritis with anakinra.
Treatment of osteoarthritis with anakinra.
复制标题
DOI：
10.1007/s11926-007-0019-9
复制
发表时间：
2007-04-01
影响因子：
5
通讯作者：
Fleischmann, Roy
中科院分区：
文献类型：
--
作者：
Iqbal, Imran;Fleischmann, Roy
骨关节炎（OA）是最常见的关节炎形式，也是世界范围内致残的主要原因之一。骨性关节炎的发病率随着年龄的增长而增加，随着寿命的延长，它将造成重大的社会经济负担。骨性关节炎没有疾病改善疗法。最近的研究强调了炎症在OA进展中的作用。白细胞介素-1似乎在疾病进展中起着重要作用。由于白细胞介素-1受体拮抗剂（IL-1Ra） anakinra已成功用于治疗类风湿关节炎的炎症和骨破坏，一些人认为它可能能够延缓OA的疾病进展。本文综述了阿那白在OA治疗中的应用。
Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of disability worldwide. The incidence of OA increases with age, and as longevity increases, it will cause a significant socioeconomic burden. No disease-modifying therapy is available for OA. Recent research has highlighted the role of inflammation in the progression of OA. Interleukin-1 appears to have a significant role in disease progression. Since the interleukin-1 receptor antagonist (IL-1Ra) anakinra has been used successfully in the treatment of the inflammation and bone destruction of rheumatoid arthritis, some have suggested that it may be able to retard the disease progression of OA. This article reviews the data on the use of anakinra in OA treatment.